Lausanne-based Hedera Dx, a BioTech firm, at the moment introduced the closing of a €15 million Sequence A financing spherical to drive superior most cancers care and overcome structural boundaries that stop most cancers sufferers from accessing focused most cancers therapies.
The spherical was led by Vsquared Ventures, with Tesi additionally becoming a member of as a brand new investor alongside participation from current backers Helsana HealthInvest, Eyrir Enterprise Administration, Inventure, and Prime Harvest.
“At Hedera, we’re constructing the infrastructure to make precision most cancers care accessible to each affected person and clinician – globally,” mentioned Tommi Lehtonen, CEO and Co-founder of Hedera Dx. “Whereas there’s a lot of personalised most cancers remedies available on the market, a really massive a part of affected person s nonetheless can’t entry them. Our options empower hospital labs to carry out subtle molecular diagnostics regionally and price effectively.”
Based in 2021, Hedera Dx is a BioTech firm devoted to eradicating boundaries to precision medication in oncology. The corporate’s built-in platform combines superior molecular diagnostics with scientific information to tell therapy selections and speed up drug growth.
Hedera’s workforce of 20+ professionals brings collectively experience in genomics, scientific oncology, bioinformatics, synthetic intelligence, and digital well being.
Dr Lise Rechsteiner, Normal Associate at Vsquared Ventures, mentioned: “Hedera Dx is addressing a vital hole in world oncology care. Hedera’s strategy tackles the particular challenges of hospital in – home testing and ends in extra sufferers getting examined and extra sufferers getting access to focused therapies . Hedera Dx’s mixture of diagnostics and highly effective real-world information capabilities positions them to turn into the definitive chief in precision oncology inside well being care methods outdoors the US.”
Hedera Dx has developed blood-based most cancers testing options, often known as liquid biopsies, to permit for price environment friendly and simple to undertake in-house testing of most cancers sufferers. The answer combines affordability with unprecedented high quality and is already deployed throughout 11 European international locations.
Along with superior molecular profiling of most cancers sufferers that gives physicians with insights for therapy selections, the AI-native platform additionally reportedly uncovers patient-centric from real-world information to help the event of subsequent era oncology remedies.
“We’re not solely bettering entry to superior most cancers look after sufferers – we’re creating a wholly new platform for real-world insights, driving entry to life-saving precision oncology remedies and fuelling the following wave of progressive most cancers therapies,” added Dr Christian Meisel, CMO and Co-founder of Hedera Dx.
The Sequence A funding will help continued business enlargement and additional growth of the corporate’s real-world information infrastructure, addressing the huge world oncology market.
